Home › Companies › DFTX

Definium Therapeutics

Market cap $4.02B 136.9M shares (10-Q, Nov 2, 2026) × $29.38 close Nov 17, 2026

Most recent annual filing: 2026-02-15

Catalyst timeline

1 trackedQuarter catalyst calendar →
  1. DT402 R-MDMA interim2026DT402 R-MDMA interim, 2026, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Capital (as filed)

Cash
$241M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$806M Sep 30, 2026
Operating cash flow
−$53.0M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$1.05B cash, runway 2030 per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (11)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (11 calls)

Every verdict Biotech Distilled has published on Definium Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Speculative buy core Definium Therapeutics, formerly MindMed (DFTX, formerly MNMD): Scientific Deep Dive for DT120 and Pipeline Products Strong Phase 2b data, secured cash runway into 2028, and asymmetric upside heading into three pivotal 2026 readouts justify a speculative buy sized for a potential 50-70% loss.
  2. Hold UPDATE: Definium (DFTX) Q4 Financial Update Thesis tracking perfectly with secure cash, strong institutional positioning, and MDD now leading the catalyst calendar; maintain and accumulate.
  3. Buy core UPDATE: Definium (DFTX) - The DEA Cloud Lifts and the Stats Get Sharper Executive Order materially de-risks DEA rescheduling overhang and Panorama SSRE results dramatically lower the statistical bar for a Phase 3 win, upgrading from speculative to core accumulate.
  4. Buy core UPDATE: Definium (DFTX) - The Pre-Readout Setup Locks In, PTSD Joins the Party Cash intact, catalyst calendar tightened to three pivotals in five months, and PTSD expansion signals internal confidence; maintain buy and accumulate into the Emerge MDD readout.
  5. Hold UPDATE: Definium (DFTX) - Emerge Hits, And They Hit the Market Emerge Phase 3 MDD delivered an 8.1-point placebo-adjusted MADRS delta validating the clinical thesis; mechanically trim post-data gains to take cost basis off the table while holding core through remaining pivotals.
  6. Hold UPDATE: Definium (DFTX) - The Raise Got Upsized, And The Greenshoe Cleared Same-Day $805M raise at favorable terms removes all financing overhang through NDA and launch; maintain trim-to-core stance with two binary pivotals still ahead in Q3.
  7. Buy core UPDATE: Definium (DFTX) - Voyage Lands Next Week, And They Quietly Bought Out Their Royalty $1.1B cash with runway into 2030, royalty burden permanently retired via Liechti Lab license buyout, and Voyage GAD pivotal readout imminent; maintain buy on the core position.
  8. Buy core UPDATE: Definium (DFTX) - Voyage Hits, And the Stock Sells Off Anyway Voyage delivered an exact Phase 2b replication (d=0.81) confirming the GAD signal; 7.3% selloff is profit-taking not a science verdict, maintain buy with Panorama as the final binary.
  9. Buy core UPDATE: Definium (DFTX) - A Second Breakthrough, And a Stock That Keeps Bleeding Second FDA Breakthrough Therapy designation in MDD confirms franchise engagement and compresses NDA timeline; 10.7% tape drift is positioning ahead of Panorama, not a science repricing.
  10. Hold UPDATE: Definium (DFTX) - Panorama Hits, And the Unblinding Elephant Finally Gets Answered Panorama's active-controlled design answered the functional unblinding objection with a clear dose-response gradient; clinical thesis is now substantially closed and the story shifts to commercial execution and DEA rescheduling.
  11. Hold UPDATE: Definium (DFTX) - The Sleeper Asset Rolls Over DT402 autism readout was only five open-label patients with no quantitative data and next study pushed to 2027; DT120 NDA on track but story is now a waiting game on regulatory and commercial execution.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (4 quotes from 4 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (41)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 7, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

7 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)